Drug Type Small molecule drug |
Synonyms |
Mechanism GCGR agonists(Glucagon receptor agonists), GIPR agonists(Gastric inhibitory polypeptide receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Obesity | Phase 3 | - | - | |
Diabetes Mellitus, Type 2 | Phase 1 | AU | 06 May 2024 |
Phase 1 | - | (aoskkfovxi) = kptypvkkfc zqzvkaickh (kgxstlknsx ) View more | Positive | 07 Oct 2024 | |||
Placebo | (aoskkfovxi) = yazkcopwoa zqzvkaickh (kgxstlknsx ) | ||||||
Not Applicable | glucose | lipids | - | mnwsqbqcfi(fdtkivlcri) = hkrtttqrpc vpgqdrgaty (xadrxwdroe ) | Positive | 14 Jun 2024 | ||
NA-932 | mnwsqbqcfi(fdtkivlcri) = axhqlzfeya vpgqdrgaty (xadrxwdroe ) |